Myeloid Malignancies Clinical Trials

24 clinical trials for Myeloid Malignancies across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies — RECRUITING · PHASE2
• Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies — RECRUITING · PHASE1
• A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies — RECRUITING · PHASE1
• A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies — RECRUITING · PHASE2
• Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial — RECRUITING · PHASE3
• Allogeneic iNKT Cell Therapy (agenT-797) After SCT — NOT_YET_RECRUITING · PHASE1
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation — TERMINATED · PHASE3
• A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies — COMPLETED · PHASE1
• Off-the-shelf NK Cells + SCT for Myeloid Malignancies — COMPLETED · PHASE2
• VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT — NOT_YET_RECRUITING · PHASE2
• Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies — NOT_YET_RECRUITING · PHASE1
• Study of Magrolimab Combinations in Participants With Myeloid Malignancies — TERMINATED · PHASE2
• Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors — COMPLETED · PHASE1
• MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies — WITHDRAWN · NA
• Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT — OTHER · PHASE2
• Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies — OTHER · PHASE2
• Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies — COMPLETED · PHASE2
• A PHASE 2, SINGLE-ARM, MULTICOHORT, OPEN LABEL, MULTICENTER TRIAL OF OFF-THE-SHELF NATURAL KILLER (NK) CELLS (SAR445419) IN PATIENTS WITH HIGH-RISK MYELOID MALIGNANCIES UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) — NOT_YET_RECRUITING · PHASE2
• Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis — COMPLETED · PHASE2
• A PHASE 1 FIRST-IN-HUMAN STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF AMG 330 ADMINISTERED AS CONTINUOUS INTRAVENOUS INFUSION IN SUBJECTS WITH MYELOID MALIGNANCIES — COMPLETED · PHASE1
• A PHASE 1 STUDY OF SAFETY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF TAS1553 IN SUBJECTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) AND OTHER MYELOID NEOPLASMS — COMPLETED · PHASE1
• A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies — OTHER · PHASE1
• A PHASE 2, OPEN-LABEL, MONOTHERAPY, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INCB054828 IN SUBJECTS WITH MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT — COMPLETED · PHASE2
• A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies — OTHER · PHASE1

Refine this search